Benign lumbar arachnoiditis: MR imaging with gadopentetate dimeglumine

MR imaging was performed in 13 patients with benign lumbar arachnoiditis both before and after IV injection of gadopentetate dimeglumine. The arachnoiditis was proved by previous myelography in 12 patients and by noncontrast MR imaging in one patient. The disease was presumably the result of previous myelography and/or surgery. It was characterized as mild in two patients, moderate in two patients, and severe in nine patients. Imaging was performed on a 1.5-T unit, and both short and long TR images were obtained before and after contrast administration. Noncontrast MR images demonstrated changes consistent with arachnoiditis in all patients. After contrast, three patients had no enhancement, three patients had minimal enhancement, three patients had mild enhancement, and four patients had moderate enhancement. In no case did contrast enhancement alter the diagnosis or reveal additional findings that could not be seen on the noncontrast images. Gadopentetate dimeglumine enhancement plays little role in the diagnosis of lumbar arachnoiditis. If used for another reason, however, short TR scans may show enhancement of adherent roots in some cases. In addition, administration of gadopentetate dimeglumine will not cause sufficient enhancement to hinder the detection of arachnoiditis on long TR images and may aid in recognition of adherent roots on short TR images.     

Optimizing brain MR imaging protocols with gadopentetate dimeglumine: enhancement of intracranial lesions on spin-density- and T2-weighted images

To determine whether long TR MR imaging is best performed before or after IV administration of gadopentetate dimeglumine, we obtained spin-density- and T2-weighted images before and after contrast administration in 21 patients with known intracranial enhancing lesions. Of 25 lesions demonstrating enhancement on T1-weighted sequences, 21 showed mild or moderate enhancement on spin-density-weighted sequences and 20 showed mild enhancement on T2-weighted sequences. Importantly, no spin-density or T2 information was obscured by the administration of gadopentetate dimeglumine, and no T2 shortening effects were visible. Two new foci of enhancement were visible on postcontrast spin-density- and T2-weighted images that were missed on postcontrast T1-weighted images and on precontrast spin-density- and T2-weighted studies. Visualization of new areas of enhancement is the main advantage provided by the long TR images obtained after IV injection of gadopentetate dimeglumine. The most likely reason for the appearance of these newly visualized lesions is thought to be delayed enhancement. This imaging protocol also allows the display of adjacent edema or gliosis and enhancing lesions on a single image. Additionally, in three cases, posterior fossa phase-shift artifacts raised the suspicion of an enhancing lesion on postcontrast T1-weighted images, but the cerebellum was shown to be normal on the postcontrast spin-density- and T2-weighted studies. On the basis of our results, we recommend obtaining long TR images after rather than before the administration of gadopentetate dimeglumine in patients with intracranial enhancing lesions.     

MR imaging of lumbar arachnoiditis

To assess the usefulness of MR in defining the changes of lumbar arachnoiditis, we reviewed retrospectively the MR, plain-film myelographic, and CT myelographic findings in 100 patients referred for evaluation of failed-back-surgery syndrome. In 11 of 12 cases of arachnoiditis demonstrated by plain-film and CT myelography, an abnormal configuration of nerve roots was seen by MR. The correlated MR and CT and plain-film myelographic changes were divided into three anatomic groups: group 1 showed conglomerations of adherent roots residing centrally within the thecal sac, group 2 demonstrated roots adherent peripherally to the meninges giving rise to an "empty-sac" appearance, and group 3 demonstrated a soft-tissue mass replacing the subarachnoid space. There was one false-negative MR study. For the diagnosis of moderate to severe arachnoiditis, we found MR to correlate excellently with CT myelographic and plain-film myelographic findings.     

Chondrosarcomas of the skull base: MR imaging features.

The magnetic resonance (MR) images from 17 patients with chondrosarcomas of the skull base were retrospectively reviewed to characterize the size, location, signal intensity, and extension of these tumors. Eleven patients with chondrosarcomas received intravenously administered gadopentetate dimeglumine. In 16 patients, computed tomographic (CT) scans were obtained to evaluate intratumorous mineralization and bone erosion. On short repetition time (TR)/echo time (TE) MR images, chondrosarcomas generally had low to intermediate signal intensity; on long TR/TE MR images, they generally had very high signal intensity. Signal heterogeneity on long TR/TE MR images was seen in 10 of 17 tumors (59%) and was caused by matrix mineralization, fibrocartilaginous elements, or both. Matrix mineralization was demonstrated with CT in seven of the 16 chondrosarcomas. Chondrosarcomas showed marked enhancement after administration of gadopentetate dimeglumine in either a heterogeneous (n = 8) or homogeneous (n = 3) pattern. The information about the size and extent of these neoplasms was important in the choice of surgical approaches for gross total resection of tumor.     

Thickened pituitary stalk on MR images in patients with diabetes insipidus and Langerhans cell histiocytosis

The MR images of four female patients with acute onset of central diabetes insipidus and pathologically confirmed Langerhans cell histiocytosis were evaluated retrospectively for evidence of lesions in the hypothalamic-pituitary axis. The examinations were conducted on a 1.5-T MR system with thin-section sagittal and coronal T1-weighted (short TR/short TE) and T2-weighted (long TR/long TE) images. Three patients underwent T1-weighted MR after IV administration of gadopentetate dimeglumine. Compared with 20 normal subjects who were evaluated with the same MR protocol, three of the four patients had a symmetrically thickened pituitary stalk that demonstrated homogeneous signal enhancement following contrast administration. The high signal intensity of the posterior lobe, which was seen in normal subjects on T1-weighted sagittal images, was absent in all four patients. Two patients had associated abnormalities on either chest films or imaging studies of the temporal bone and two patients had isolated CNS Langerhans cell histiocytosis. The combination of a thickened pituitary stalk and absent posterior pituitary hyperintensity, while nonspecific for Langerhans cell histiocytosis, should nevertheless prompt further studies, such as chest films, bone scanning, or temporal bone CT, to attempt to narrow the differential diagnosis. Gadopentetate dimeglumine, in particular, may be a useful adjunct in the MR examination of the patient with diabetes insipidus.     

MR imaging features of medulloblastomas.

The preoperative MR studies of 25 patients with surgically proved medulloblastomas were retrospectively reviewed in order to characterize these neoplasms with regard to their MR signal intensity, size, location, and appearance after contrast enhancement. Gadopentetate dimeglumine--enhanced MR images were available in 11 patients. On short TR/short TE images, medulloblastomas generally had low to intermediate signal, and were predominantly slightly hyperintense relative to muscle and hypointense relative to white matter. On long TR/long TE images, medulloblastomas generally had intermediate to moderately high signal, predominantly hyperintense relative to muscle and white matter. Tumor signal relative to gray matter varied considerably on both short TR and long TR images. Signal heterogeneity on long TR/long TE images was observed in 91% of the lesions and resulted from intratumoral cystic zones, small blood vessels, and/or calcifications. In the patients who received gadopentetate dimeglumine, the fraction of tumor volume showing enhancement was found to be less than one third in two cases, between one third and two thirds in four cases, and greater than two thirds in five cases. The mean tumor size was 3.6 x 4.0 x 3.5 cm. The most frequent location of medulloblastoma was the mid and inferior vermis. We conclude that the unenhanced and enhanced MR characteristics of medulloblastomas are somewhat variable. Medulloblastomas should be included in the differential diagnosis when the MR findings described are present in the appropriate patient population.     

Inverted papilloma: evaluation with MR imaging.

The authors examined the magnetic resonance (MR) appearance of inverted papillomas to determine if this histologically benign lesion could be distinguished from malignancies of the sinonasal cavity. MR images in 10 patients with histologically proved inverted papilloma were retrospectively reviewed. The signal intensity of inverted papillomas on short repetition time (TR) images was iso- to slightly hypertintense to muscle in all 10 patients. Inverted papillomas had intermediate signal intensity on the long TR/echo time (TE) images. The tumors were iso- or slightly hypointense to fat on long TR/short TE images. In the seven patients who received gadopentetate dimeglumine, all inverted papillomas showed solid inhomogeneous enhancement. A review of eight sinonasal malignancies showed no distinctive signal intensity or enhancement characteristics to help differentiate inverted papillomas from various malignant tumors. The authors conclude that there is no signature MR appearance for the benign inverted papilloma. The main utility of MR imaging is in defining the extent of the lesion.     

MR imaging of Sturge-Weber syndrome: role of gadopentetate dimeglumine and gradient-echo techniques

Five patients with Sturge-Weber syndrome were evaluated by conventional noncontrast spin-echo MR imaging, a gradient-recalled echo (GRE) technique, and T1-weighted spin-echo imaging after administration of gadopentetate dimeglumine. In four of five cases the full extent of intracranial disease was appreciated only on the postcontrast images. In one patient precontrast and GRE images were entirely normal, while only the postcontrast study demonstrated extensive involvement of both brain and retina. Nevertheless, some abnormal vessels with higher flows were seen better on precontrast T2-weighted images than on postcontrast T1-weighted images. GRE techniques demonstrated calcifications to best advantage, in one case even better than on CT. Contrast enhancement with gadopentetate dimeglumine is necessary for the complete MR evaluation of patients with suspected Sturge-Weber syndrome. Traditional noncontrast T2-weighted and GRE images may provide additional complementary information.     

Gadopentetate dimeglumine as a bowel contrast agent: safety and efficacy

To determine the safety and efficacy of gadopentetate dimeglumine as a bowel contrast agent, magnetic resonance (MR) imaging (0.5 T) was performed with a formulation of gadopentetate dimeglumine (1.0 mmol/L of gadopentetate dimeglumine, 15 g/L of mannitol, 6-17 mL/kg) in 133 patients with intraabdominal mass lesions. Mostly short-lived gastrointestinal side effects were noted in 32% of patients. Gadopentetate dimeglumine provided uniform hyperintense marking of the bowel and contrast enhancement in the region of interest in 81% of patients. Among 78 patients with images obtained both before and after administration of contrast material, post-contrast improvement of lesion delineation was found in 62%. Among 55 patients with only postcontrast images, gadopentetate dimeglumine proved useful in 65%. Intravenous injection of scopolamine or glucagon effectively eliminated "ghost" images of the opacified bowel in 105 of 109 cases. The authors conclude that gadopentetate dimeglumine is a safe and effective bowel contrast agent for MR imaging.     

Efficacy and safety of gadopentetate dimeglumine in the evaluation of patients with a suspected tumor of the extracranial head and neck

The clinical efficacy and safety of gadopentetate dimeglumine as a paramagnetic contrast agent for magnetic resonance (MR) imaging of the extracranial head and neck was evaluated in a multicenter trial involving 60 patients. Patients with signs and/or symptoms of a tumor in the nasopharynx, oropharynx, hypopharynx, larynx, or neck were studied. T1-weighted images were obtained before and after injection of gadopentetate dimeglumine, 0.1 mmol/kg, at a rate of 10 mL/min. No lesions were seen on the pre- or postinjection images of five of the 60 patients. Postinjection lesion enhancement was present in 53 of the remaining 55 (96%) patients. The absence of postinjection lesion enhancement in one of the two remaining patients was useful information. Postinjection impressions differed from preinjection diagnosis in 22 of 60 (37%) patients. Additional information was obtained from postinjection relative to preinjection images in 38 of 60 (63%) patients. Four adverse experiences were reported in three of 60 (5%) patients. Two mild (chest wall pain and headache) and one moderate (nausea) adverse experiences were considered by the authors to be unrelated to the studied drug. One severe adverse experience was reported. This patient had a seizure, considered by the investigator to be remotely related to the study drug and attributed to the abrupt withdrawal of anticonvulsant medications. The data indicate that gadopentetate dimeglumine is safe and efficacious in the evaluation of patients with extracranial head and neck lesions.     

MR imaging of the brain in patients with migraine headaches

Forty-one patients with migraine headaches were referred for MR imaging of the brain. Intermediate and T2-weighted images were obtained to determine the frequency of areas of high intensity within the white matter. The average age of these patients was 29.8 years; only five were over 40 years old. Each patient was evaluated in the axial plane with long TR/short and long TE images. Twenty-three patients also had T1-weighted short TR/short TE MR scans; enhancement with gadopentetate dimeglumine was used in three patients. Intracranial abnormalities were seen in only six patients: foci or white matter high intensity on intermediate and T2-weighted images in five and a venous angioma in one. Prior studies have indicated that parenchymal brain abnormalities may be found in up to 46% of patients with migraines. The current study demonstrated parenchymal brain lesions in only 12%. This study suggests that the frequency of foci of high intensity seen on long TR sequences in the migraine patient is much lower than previously reported, especially in patients under 40 years old (5.5% in our series).     

Normal venous anatomy of the brain: demonstration with gadopentetate dimeglumine in enhanced 3-D MR angiography

This investigation evaluates whether gadopentetate dimeglumine enhancement of three-dimensional (3-D) acquisition MR angiography can generate clinically useful images of the normal venous anatomy of the brain. 3-D MR angiography of normal cerebral arterial anatomy has made rapid progress, although demonstration of detailed venous anatomy with similar techniques has been much less revealing. To overcome the limitation of slow venous flow, IV gadopentetate dimeglumine contrast enhancement was used to alter the relaxation times of blood, thus augmenting the venous signal. Several groups of patients were evaluated: we studied eight patients both with and without contrast enhancement, 20 patients and volunteers with multiple techniques to determine optimal technical parameters, and seven patients in whom enhanced MR studies were compared with standard selective biplane cut-film arterial angiograms. Only the large dural sinuses (such as the transverse sinus) could be seen on unenhanced studies owing to the saturation of slowly flowing venous spins. With contrast enhancement, many of the important small and large cerebral venous structures were routinely seen with reasonable scanning times (7 min). The venous anatomy was well seen for approximately one-half hour after injection and correlated well with angiograms. There are several important limitations to this technique, including a limited field of view, variable visibility of specific veins owing to technical and physiologic factors, confusion of enhancing non-flow-related structures, and lack of detailed physiologic information. Single excitation 3-D MR angiograms are insensitive in the evaluation of cerebral venous structures. Enhancement with gadopentetate dimeglumine affords rapid scanning and excellent visualization of the pertinent venous anatomy. The best image quality was obtained with a sequence of 50/7/30 degrees (TR/TE/flip angle).     

Combined gadolinium-enhanced and fat-saturation MR imaging of renal masses

Combined gadopentetate dimeglumine enhancement and fat-saturation (FS) spin-echo (SE) magnetic resonance (MR) imaging for the detection and characterization of renal masses was evaluated in 43 patients with a total of 71 lesions (28 solid masses and 43 cysts). SE MR sequences compared were the following: short repetition time (TR)/echo time (TE), conventional SE, short TR/TE FS SE, long TR/TE conventional SE, gadolinium-enhanced short TR/TE conventional SE, and gadolinium-enhanced short TR/TE FS SE techniques. MR findings were compared with findings of contrast-enhanced computed tomography (CT) and with pathologic findings in all patients. The sensitivities for detection of renal masses with gadolinium-enhanced FS (71 of 71 lesions) and with gadolinium-enhanced short TR/TE conventional (65 of 71 lesions) SE sequences were significantly (P less than .01) greater than with any unenhanced (short TR/TE conventional [40 of 71 lesions], or long TR/TE [39 of 71 lesions]) SE sequence. Lesion characterization was also best with the gadolinium-enhanced FS SE sequence (65 of 71 lesions correctly classified). When combined pre- and postcontrast short TR/TE FS SE images were analyzed with both qualitative (visual) and quantitative (region-of-interest measurements) assessment, lesion characterization improved even further (70 of 71 lesions were correctly characterized). All lesions detected with CT were visualized with the gadolinium-enhanced FS SE MR sequence, which in addition depicted seven cysts and two small renal cell carcinomas. In summary, the use of gadopentetate dimeglumine, especially when combined with the FS technique, was superior to unenhanced MR imaging for detection and characterization of renal lesions.     

Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT

Contrast-enhanced MR studies were compared with noncontrast MR and contrast-enhanced CT scans in the evaluation of intraparenchymal brain metastases. Fifty consecutive inpatients were studied with short and long repetition time (TR) sequences before and after the administration of gadopentetate dimeglumine. In addition, a delayed short TR sequence was performed. The contrast CT, noncontrast MR, immediate postcontrast short TR sequence, postcontrast long TR sequence, and delayed postcontrast short TR sequence were each read blindly and independently by two neuroradiologists. These results were then compared with a final interpretation, reached by all the neuroradiologists in the study, using all the clinical information and imaging findings. Postcontrast short TR scans proved to be superior to other sequences. They were particularly useful in the detection of metastases in the posterior fossa and cortex. The delayed postcontrast short TR scan held no definite advantage over the immediate postcontrast short TR scan, although metastases were sometimes seen slightly better after the delay. While long TR sequences were not always sensitive or specific, they often did provide ancillary information and were particularly useful in cases of hemorrhagic metastases. Because of these findings, we recommend that the evaluation of intraparenchymal metastases consist of a single postcontrast long TR scan followed by a single postcontrast short TR scan. While these sequences should be very accurate in the detection of metastases, we also generally perform a single precontrast short TR scan as well, since the question of hemorrhage or bone lesion may be clinically relevant.     

Enhancement of intervertebral disks with gadolinium complexes: comparison of an ionic and a nonionic medium in an animal model.

PURPOSETo compare MR contrast enhancement of intervertebral disk tissue after intravenous administration of equimolar doses of an ionic and of a nonionic gadolinium complex.METHODSContrast enhancement was measured on MR in lumbar intervertebral disks for 120 minutes after intravenous injection of gadoteridol or gadopentetate dimeglumine, 0.3 mmol/kg. MR studies were performed with each contrast medium in four rabbits. Contrast enhancement was measured in intervertebral disks as a function of time and contrast medium.RESULTSWith both contrast media, enhancement of normal intervertebral disks was detected. Enhancement of disks was significantly greater with gadoteridol than with gadopentetate dimeglumine.CONCLUSIONThe enhancement of cartilage is influenced by the molecular structure of the gadolinium complex. The negative charge of gadopentetate dimeglumine may give it a slower rate of diffusion into disk cartilage than a nonionic complex.     

Spleen: dynamic enhancement patterns on gradient-echo MR images enhanced with gadopentetate dimeglumine.

To examine the pattern of immediate enhancement with gadopentetate dimeglumine on dynamic magnetic resonance (MR) images of the spleen, this study was divided into two parts: In the first part, the authors retrospectively reviewed the dynamic MR images obtained with a fast low-angle shot (FLASH) sequence in the abdomen immediately after injection of gadopentetate dimeglumine in 137 patients. In the second part, dynamic gadolinium-enhanced FLASH images were prospectively compared with contrast material-enhanced computed tomographic (CT) scans in 17 patients with focal splenic lesions discovered on CT scans. In the first part, 108 patients (79%) had an arciform pattern of contrast enhancement; 22 patients (16%), a uniform pattern of high signal intensity; and seven patients (5%), a uniform pattern of low signal intensity. Most patients had arciform enhancement of the spleen; uniform enhancement occurred in some patients with underlying malignant or inflammatory disease. In the second part, all focal lesions seen on CT scans were seen on dynamic MR images (75 lesions), significantly more than were seen on FLASH images (15 lesions) (P < .001).     

Gadopentetate dimeglumine-enhanced MR of the brain: clinical utility and safety in patients younger than two years of age.

PURPOSETo evaluate the clinical utility and safety of gadopentetate dimeglumine as a contrast agent for MR of the brain in patients younger than 2 years of age.METHODSIn 125 consecutive patients younger than 2 years of age, MR images obtained before and after gadopentetate dimeglumine administration (0.1 mmol/kg) were independently and prospectively evaluated. After interpreting the unenhanced T1- and T2-weighted images, we rated the utility of contrast administration in each patient as not helpful, helpful, or essential for formulation of the radiologic diagnosis. Ratings were categorized both on the basis of the referring clinical diagnoses and on the basis of a radiologic diagnosis that was established from the clinical history and from the findings on the precontrast and postcontrast T1- and T2-weighted images. Patients'' vital signs were recorded, and general medical status was observed for 120 minutes after gadopentetate dimeglumine administration.RESULTSIn no case did gadopentetate dimeglumine permit detection of lesions when precontrast T1- and T2-weighted images were normal. In only 4 of 125 patients were postcontrast images considered essential for establishing the radiologic diagnosis. Abnormal contrast enhancement was radiologically helpful in 20 of 125 patients. Lack of enhancement was considered helpful in 22 of 125 patients. No adverse clinical events or clinically important trends in vital signs were observed after contrast administration.CONCLUSIONThe indiscriminate use of contrast agents in the MR imaging of patients younger than 2 years of age is not warranted. Appropriate decisions regarding the use of gadopentetate dimeglumine can be based on the findings in unenhanced T1- and T2-weighted images and on the referring clinical diagnosis.     

Preoperative evaluation of osteosarcoma: value of gadopentetate dimeglumine-enhanced MR imaging.

Decisions regarding the surgical approach in osteosarcoma require accurate assessment of tumor extent. In order to determine whether enhancement with gadopentetate dimeglumine could add clinically significant information to that available with unenhanced MR imaging, 21 patients with osteosarcoma underwent preoperative MR imaging. T1- and T2-weighted spin-echo MR images obtained before and after administration of IV gadopentetate dimeglumine were evaluated to determine the conspicuity of marrow and soft-tissue extent of tumor, including tumor involvement of major neurovascular bundles and adjacent joints. MR results were correlated with tumor margins found at surgery. In some instances, use of gadopentetate dimeglumine obscured differentiation of tumor from normal marrow or tumor infiltration into perineurovascular fat, and tumor extension through pseudocapsule could not be differentiated from peritumoral edema after contrast administration. Contrast enhancement did assist in differentiation of intraarticular tumor from effusion; however, synovial invasion could be identified on unenhanced T1-weighted images by loss of synovial fat and cortical disruption. These results indicate that gadopentetate dimeglumine does not assist in defining tumor margins of osteosarcoma.     

Gadolinium-enhanced magnetization transfer contrast imaging of intracranial tumors.

The magnetization transfer contrast (MTC) technique was used in low-field-strength (0.1 T) magnetic resonance (MR) imaging of 28 patients with intracranial tumors. MTC images were generated with an off-resonance, low-power radio-frequency pulse applied during the interpulse delay period of a gradient-echo partial-saturation sequence (TR msec/TE msec = 200/20). Images in the presence and absence of the MTC pulse were concurrently acquired before and after injection of gadopentetate dimeglumine at a dose of 0.1 mmol/kg. The contrast agent enhanced 27 of 28 tumors. Application of the MTC pulse improved the contrast-to-noise ratio (C/N) between tumor and normal white matter in 26 of 28 cases on the preinjection images and in 25 of 28 cases on the postinjection images. On the gadolinium-enhanced images, the mean C/N was 2.6 +/- 1.7 without the MTC pulse and 3.2 +/- 1.9 with the MTC pulse. The greatest contrast improvement with the MTC technique was obtained in tumors showing the strongest paramagnetic enhancement. The results indicate that MTC can improve contrast between normal brain and some intracranial neoplasms. The use of gadopentetate dimeglumine generally intensified this effect.     

MR imaging of the stomach: potential use for mangafodipir trisodium--a study in swine

PURPOSE: To evaluate mangafodipir trisodium as a potential contrast agent at magnetic resonance (MR) imaging of the stomach. MATERIALS AND METHODS: Mangafodipir trisodium was injected intravenously into three swine at a dose of 5 micromol per kilogram of body weight. For comparison, gadopentetate dimeglumine was injected into three other swine at a dose of 0.1 mmol per kilogram of body weight. T1-weighted three-dimensional MR images were acquired in all six swine at 1.5 T before and approximately 10, 15, 20, 25, 30, and 40 minutes after contrast material administration. Extracted stomach specimens were imaged at 3.0 T. In vivo and ex vivo images were evaluated visually and quantitatively for contrast enhancement of the stomach, and in vivo images were evaluated for the presence of reflux from the duodenum. RESULTS: Mangafodipir trisodium produced prolonged and selective enhancement of the inner surface of the stomach, in contrast to the more general enhancement seen with gadopentetate dimeglumine, and reflux from the duodenum could not account for this selective enhancement. Ex vivo images confirmed that T1 enhancement in the stomach wall with mangafodipir trisodium was limited to the inner surface. Gadopentetate dimeglumine did not produce selective enhancement of the inner surface of the stomach. CONCLUSION: Mangafodipir trisodium preferentially enhances the inner surface of the stomach on MR images acquired in swine and, therefore, may have potential for use as a contrast agent at MR imaging of the human stomach.